康柏西普治疗息肉样脉络膜血管病变的临床观察  

Clinical observation on Conbercept for the treatment of polypoidal choroidal vasculopathy

作　　者：林国乔[1] 郑德志[1] 陈浩宇[1] 刘昕宇[1] 陈伟奇[1] 

机构地区：[1]汕头大学·香港中文大学联合汕头国际眼科中心玻璃体视网膜专科,广东汕头515000

出　　处：《中华眼外伤职业眼病杂志》2017年第8期570-574,共5页Chinese Journal of Ocular Trauma and Occupational Eye Disease

基　　金：广东省医学科学技术研究基金（B2016096）

摘　　要：目的观察玻璃体内注射康柏西普（Conbercept）治疗息肉样脉络膜血管病变的效果。方法回顾性分析41例（41只眼）息肉样脉络膜血管病变（PCV）的临床资料。患者接受玻璃体内注射康柏西普（0．05ml／次，10mg／ml），并根据病情决定是否重复注射。随访1．4～14．5个月，平均（4．38±3．08）个月，观察治疗效果。结果注药前BCVA平均为0．94±0．62（10gMAR）；黄斑中心区视网膜厚度（CMT）平均为（294．66±102．81）μm；黄斑中心凹厚度（MT）平均为（289．27±71．08）um。所有患者OCT扫描均提示存在视网膜神经上皮层浅脱离。末次注射后BCVA（10gMAR）平均为0．71±0．38；CMT平均为（257．90±99．60）μm；MT平均为（217．4±122．63）±m。治疗前后差异均有统计学意义（P〈0．01）。90．2％的患者视力得到了改善或稳定，39．O％的患者黄斑区神经上皮脱离消失。结论康柏西普玻璃体内注射可以有效改善PCV患者的视力，降低视网膜厚度。Objective To observe the efficacy of intravitreal injection of Conbercept for the treatment of polypoidal choroidal vasculopathy（PCV）. Methods The data of 41 eyes of 41 patients with PCV were collected and analyzed retrospectively, they all received intravitreal injection of Conbercept （0. 05 ml, 10 mg/ml）. Some cases received injection once again according to the state of the illness. The follow-up time was 1.4-14.5 months, average （4.38 ± 3.08） months. The efficacy was observed. Results After the last injection, the BCVA （log MAR） improved from 0.94 ±0.62 to O. 71 ±0.38, the CMT decreased from （ 294.66 ± 102.81 ） μm to （ 257.90 ± 99.60） μm, and the MT decreased from （ 289.27 ± 171.08 ） μm to （217.4 ±122.63 ）μm, the difference in BCVA, CMT and MT were statistically significant between before and after injection （ P 〈 0. 01 ）. The visual acuity improved or stabilized in 90. 2% patients. The neurosensory layer detachment of macular retina relieved in 39.0% of patients. Conclusion ]ntravitreal injection of Conbercept can improve visual acuity and reduce macular thickness in PCV patients.

关 键 词：脉络膜血管病变 息肉样 康柏西普 玻璃体内注射 

分 类 号：R773.4[医药卫生—眼科]